Focus: Humanwell Pharmaceutical is a publicly traded specialty pharma company headquartered in Ballwin, Missouri, focused on anesthetic and pain medications with a diversified portfolio spanning neurology, cardiovascular, endocrinology, oncology, and nephrology.
Profile data last refreshed 8h ago · AI intelligence enriched 2w ago
No open roles listed right now. Follow Humanwell Pharmaceutical to get notified when they start hiring — the background below is worth knowing for when they do.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for Humanwell Pharmaceutical
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Humanwell Pharmaceutical's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Lead revenue generator and mu-opioid/norepinephrine reuptake inhibitor; faces loss of exclusivity in 18 months.
Extended-release formulation with longer patent runway; $53M cliff in 2029 represents significant future revenue loss.
Off-patent generic ANDA; stable cash contributor in neurology.
Class IC antiarrhythmic generic; stable cardiovascular franchise contributor.
Off-patent generic ANDA in psychiatry/neurology; lower-margin but stable revenue.
Xanthine oxidase inhibitor generic; oncology and nephrology support product.
Cholinesterase inhibitor generic in neurology; lowest-revenue product in portfolio.
Minimal-revenue ANDA formulation; likely niche or legacy presentation.
Minimal-revenue ANDA formulation; likely niche or legacy presentation.
Minimal-revenue ANDA formulation; likely niche or legacy presentation.
30 discontinued, 51 duplicate formulations not shown
No open positions listed yet. Check their careers page directly.
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/moSource: USCIS H-1B Employer Data Hub
+28 more products